Kuros Biosciences H1-2025

capital, with cash and cash equivalents totaling USD 18.4 million as of June 30, 2025 (December 31, 2024: USD 19.8 million) Reporting currency changed from CHF to USD to align with the Group’s primary market and operational footprint in the U.S. The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027